Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MS4A6A (Membrane-spanning 4-domains subfamily A member 6A) is a member of the MS4A gene family, defined by four transmembrane domains, and is primarily expressed in microglia in the brain. It acts as a regulator of microglial immune function, participates in signal transduction within multimeric receptor complexes, and modulates inflammatory responses. MS4A6A genetic variants are implicated in the risk for Alzheimer’s disease and other neurodegenerative disorders through their influence on amyloid-beta clearance and inflammatory pathways. While no drugs currently target MS4A6A directly, understanding its biology supports ongoing research into microglia and neurodegenerative disease therapy.
For potential modulators: Regulation of microglia activation, inflammation suppression (JAK2/NF-κB signaling), and enhancement of amyloid-beta phagocytosis. Targeting transcription/expression levels via SNPs that modulate MS4A6A abundance, which correlates to AD risk and biomarker changes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Membrane-spanning 4-domains subfamily A member 6A (MS4A6A).